PEL

Piramal Enterprises Limited has informed the Exchange about Merger of Piramal Enterprises Limited with Piramal Finance Limited

Piramal Enterprises Limited has informed the Exchange about effectiveness of the Composite Scheme of Arrangement amongst Piramal Enterprises Limited, Piramal Finance Limited (formerly known as Piramal Capital & Housing Finance Limited) and their respective shareholders and creditors

Piramal Enterprises Limited has informed the Exchange about Receipt of Order passed by the Honble National Company Law Tribunal, Mumbai Bench, approving the Composite Scheme of Arrangement amongst Piramal Enterprises Limited, Piramal Finance Limited (Formerly known as Piramal Capital & Housing Finance Limited) and their respective shareholders and creditors.

Piramal Enterprises Limited has informed the Exchange regarding 'Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) - Filing of Company Petition in Company Application no. CA(CAA) 113 of 2025 with Hon'ble National Company Law Tribunal, Mumbai Bench.

Piramal Enterprises Limited has informed the Exchange regarding Intimation under Regulation 30 and 51 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

In connection with the composite scheme of arrangement amongst the Company, Piramal Finance Limited and their respective shareholders and creditors, the Company has received an Order from the Hon ble National Company Law Tribunal, Mumbai Bench

Piramal Enterprises Limited has informed the Exchange about Modification to the composite scheme of arrangement amongst the Company, Piramal Finance Limited (formerly known as Piramal Capital & Housing Finance Limited)and their respective shareholders and creditors.

Piramal Enterprises Limited has informed the Exchange about Acquisition

Piramal Enterprises Limited has informed the Exchange about Acquisition

Piramal Enterprises Limited has informed the Exchange about Amendment to the Composite Scheme of Arrangement between the Company and Piramal Capital & Housing Finance Limited and their respective shareholders and creditors

Piramal Enterprises Limited has informed the Exchange about completion of acquisition

Intimation under Regulations 30 and 51 of Securities and Exchange Board of India (ListingObligations and Disclosure Requirements) Regulations, 2015, as amended

Piramal Enterprises Limited has informed the Exchange about Acquisition

Piramal Enterprises Limited has informed the Exchange about Acquisition

Piramal Enterprises Limited has informed the Exchange about Intimation under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended and Securities and Exchange Board of India���s circular no. CIR/CFD/CMD/4/2015 dated September 9, 2015

Piramal Enterprises Limited has informed the Exchange about Certified copy of order passed by by Hon���ble National Company Law Tribunal, Mumbai Bench sanctioning the Scheme.

Intimation under Regulations 30 and 51 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended - Sanction of Scheme by Hon'ble National Company Law Tribunal, Mumbai Bench

Piramal Enterprises Limited has informed the Exchange about Demerger

Piramal Enterprises Limited has informed the Exchange about Acquisition

Piramal Enterprises Limited has informed the Exchange about Acquisition

Piramal Enterprises Limited has informed the Exchange about Acquisition

Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in connection with Scheme of Amalgamation of Piramal Phytocare Limited with Piramal Enterprises Limited and their respective Shareholders

Piramal Enterprises Limited has informed the Exchange about Amalgamation/Merger

Piramal Healthcare Limited has informed the Exchange that the Hon'ble Bombay High Court on November 25, 2011 has sanctioned the Scheme of Arrangement for Demerger of the NCE Research Unit of Piramal Life Sciences Limited into Piramal Healthcare Limited. Shareholders of Piramal Life Sciences Limited ('PLSL') to receive the equity shares of Piramal Healthcare Limited ('PHL') in the ratio of 1:4 (i.e. one share of Rs. 2 each of PHL for every 4 shares of Rs. 10/- each held in PLSL) under the aforesaid scheme.

Nicholas Piramal India Ltd. has informed the Exchange that the Hon'ble High court of Judicature at Bombay has vide its Order dated January 25, 2008 sanctioned the scheme Amalgamation of NPIL Healthcare Private Limited (NHPL) and Nicholas Piramal Consumer Products Private Limited (NPCPL) (the Transferor Companies) with the Company. Certified Copies of the Orders, which were received by NHPL and NPCPL from the Bombay High Court have been filed with the Registrar of Companies (ROC), Maharashtra Mumbai on February 19, 2008. Accordingly, the Scheme has now become effective. Since the Transferor Com

Nicholas Piramal India Ltd. has informed the Exchange vide their letter dated October 05, 2007, that: "The duly authorised Committee of Directors have today approved the merger of the Company's wholly-owned subsidiary, NPIL Healthcare Pvt. Ltd. with the Company".

Nicholas Piramal India Ltd. has informed the Exchange vide its letter dated August 31, 2007, that: "The Board of Directors at its Meeting held today, approved the proposal of de-merging its New Chemical Entity (NCE) Research Unit under a Scheme of Arrangement into a separate company (Transferee Company) in which Nicholas Piramal India Limited (NPIL) will hold equity capital of Rs.5 crores. Under the proposed Demerger Scheme, the NCE Undertaking with net assets (at book value) inclusive of unutilized monies collected under the Rights Issue of 2005 and intended for R&D to the extent of Rs. 95 cr

Nicholas Piramal India Ltd. has informed the Exchange on July 25, 2007 that "The Board has also today approved a proposal for merger of the Company's wholly owned subsidiary, Nicholas Piramal Consumer Products Pvt. Ltd.(formerly known as Boots Piramal Healthcare Pvt. Ltd.) with the Company".

Nicholas Piramal India Ltd. has informed the Exchange that the acquisition of Pfizer's Morpeth UK Facility has been completed on June 19, 2006 as scheduled. As mentioned earlier, the acquisition has been effected by NPIL through its wholly owned subsidiary in the UK viz. NPIL Pharmaceuticals (UK) Limited. (earlier, Avecia Pharmaceuticals, UK).

Nicholas Piramal India Ltd. has informed the Exchange that the BOD's of the Company have at the meeting held on December 17, 2004, approved the acquisition of the global Inhalation Anaesthetics (IA) business of Rhodia Organique Fine Limited (Rhodia), U.K., for a consideration of USD 14 million. This business recorded sales of USD 14 million in 2003, and gives NPIL a significant presence in the niche global IA market. This acquisition gives NPIL access to the manufacturing technology and facilities, as well as the global sales and marketing rights for two IA products - Halothane and Isofluorane